MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. MyoKardia’s initial focus is on small molecule therapeutics aimed at the myocardium to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction.
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth? No
ACC.21 Learning Pathways? (select all that apply) Heart Failure and Cardiomyopathies